<DOC>
	<DOCNO>NCT01709253</DOCNO>
	<brief_summary>Phase 2 hypofractionation study usion proton beam therapy prostate adenocarcinoma</brief_summary>
	<brief_title>Phase 2 Hypofractionation Study Using Proton Beam Therapy Prostate Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Biopsy proven prostate adenocarcinoma Stage : T1T2cN0M0 ECOG performance status : 02 Signed study specific inform consent prior study entry Postoperative residual recurrent tumor Evidence distant metastasis Previous irradiation tumor location Adjuvant antiandrogenic hormonal therapy High risk group ( NCCN guide line )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hpofractionation study use proton beam therapy</keyword>
</DOC>